JP2005517654A - 日周期リズム障害の治療方法 - Google Patents

日周期リズム障害の治療方法 Download PDF

Info

Publication number
JP2005517654A
JP2005517654A JP2003552289A JP2003552289A JP2005517654A JP 2005517654 A JP2005517654 A JP 2005517654A JP 2003552289 A JP2003552289 A JP 2003552289A JP 2003552289 A JP2003552289 A JP 2003552289A JP 2005517654 A JP2005517654 A JP 2005517654A
Authority
JP
Japan
Prior art keywords
antagonist
neuropeptide
sleep
mammal
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003552289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517654A5 (enExample
Inventor
マクニール，ダグラス・ジエイ
シヤーマン，ローレン・ピー
フアン・デル・プルーフ，レオナルドウス・ハー・テー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2005517654A publication Critical patent/JP2005517654A/ja
Publication of JP2005517654A5 publication Critical patent/JP2005517654A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003552289A 2001-12-17 2002-12-13 日周期リズム障害の治療方法 Pending JP2005517654A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34217701P 2001-12-17 2001-12-17
PCT/US2002/040015 WO2003051356A1 (en) 2001-12-17 2002-12-13 Method for treating circadian rhythm disruptions

Publications (2)

Publication Number Publication Date
JP2005517654A true JP2005517654A (ja) 2005-06-16
JP2005517654A5 JP2005517654A5 (enExample) 2007-05-17

Family

ID=23340700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003552289A Pending JP2005517654A (ja) 2001-12-17 2002-12-13 日周期リズム障害の治療方法

Country Status (6)

Country Link
US (1) US20050107411A1 (enExample)
EP (1) EP1463499A1 (enExample)
JP (1) JP2005517654A (enExample)
AU (1) AU2002351381B2 (enExample)
CA (1) CA2469790A1 (enExample)
WO (1) WO2003051356A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007145763A (ja) * 2005-11-28 2007-06-14 Tokyo Medical & Dental Univ 記憶障害抑制剤
KR101332243B1 (ko) * 2011-01-24 2013-11-25 애니젠 주식회사 생체리듬 조절용 조성물, 생체 리듬 장애 진단용 조성물 및 진단 키트

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8396565B2 (en) 2003-09-15 2013-03-12 Medtronic, Inc. Automatic therapy adjustments
MXPA06003393A (es) * 2003-09-26 2006-06-08 Pfizer Prod Inc Tratamiento de trastornos neurologicos relacionados con alteraciones del sueno de movimientos oculares rapidos (rem) con antagonistas de receptor npy y5.
JP2007506728A (ja) * 2003-09-26 2007-03-22 ファイザー・プロダクツ・インク 概日リズム障害を治療するためのｎｐｙｙ５受容体アンタゴニストの使用
US7366572B2 (en) 2004-03-16 2008-04-29 Medtronic, Inc. Controlling therapy based on sleep quality
WO2005089646A1 (en) 2004-03-16 2005-09-29 Medtronic, Inc. Sensitivity analysis for selecting therapy parameter sets
US7491181B2 (en) * 2004-03-16 2009-02-17 Medtronic, Inc. Collecting activity and sleep quality information via a medical device
US8725244B2 (en) 2004-03-16 2014-05-13 Medtronic, Inc. Determination of sleep quality for neurological disorders
US7717848B2 (en) 2004-03-16 2010-05-18 Medtronic, Inc. Collecting sleep quality information via a medical device
US7395113B2 (en) 2004-03-16 2008-07-01 Medtronic, Inc. Collecting activity information to evaluate therapy
US7330760B2 (en) 2004-03-16 2008-02-12 Medtronic, Inc. Collecting posture information to evaluate therapy
US7313440B2 (en) 2004-04-14 2007-12-25 Medtronic, Inc. Collecting posture and activity information to evaluate therapy
US7957809B2 (en) 2005-12-02 2011-06-07 Medtronic, Inc. Closed-loop therapy adjustment
US8744587B2 (en) 2006-03-24 2014-06-03 Medtronic, Inc. Collecting gait information for evaluation and control of therapy
US8688225B2 (en) 2008-07-11 2014-04-01 Medtronic, Inc. Posture state detection using selectable system control parameters
US9440084B2 (en) 2008-07-11 2016-09-13 Medtronic, Inc. Programming posture responsive therapy
US9050471B2 (en) 2008-07-11 2015-06-09 Medtronic, Inc. Posture state display on medical device user interface
US8504150B2 (en) 2008-07-11 2013-08-06 Medtronic, Inc. Associating therapy adjustments with posture states using a stability timer
US8644945B2 (en) 2008-07-11 2014-02-04 Medtronic, Inc. Patient interaction with posture-responsive therapy
US8437861B2 (en) 2008-07-11 2013-05-07 Medtronic, Inc. Posture state redefinition based on posture data and therapy adjustments
US8282580B2 (en) 2008-07-11 2012-10-09 Medtronic, Inc. Data rejection for posture state analysis
US9327070B2 (en) 2009-04-30 2016-05-03 Medtronic, Inc. Medical device therapy based on posture and timing
US8231555B2 (en) 2009-04-30 2012-07-31 Medtronic, Inc. Therapy system including multiple posture sensors
US9956418B2 (en) 2010-01-08 2018-05-01 Medtronic, Inc. Graphical manipulation of posture zones for posture-responsive therapy
US8579834B2 (en) 2010-01-08 2013-11-12 Medtronic, Inc. Display of detected patient posture state
US8758274B2 (en) 2010-01-08 2014-06-24 Medtronic, Inc. Automated adjustment of posture state definitions for a medical device
US9357949B2 (en) 2010-01-08 2016-06-07 Medtronic, Inc. User interface that displays medical therapy and posture data
US9566441B2 (en) 2010-04-30 2017-02-14 Medtronic, Inc. Detecting posture sensor signal shift or drift in medical devices
US9907959B2 (en) 2012-04-12 2018-03-06 Medtronic, Inc. Velocity detection for posture-responsive therapy
US9737719B2 (en) 2012-04-26 2017-08-22 Medtronic, Inc. Adjustment of therapy based on acceleration
CN105492010B (zh) * 2013-08-19 2020-01-03 豪夫迈·罗氏有限公司 用于治疗相移睡眠障碍的V1a拮抗剂
US11596795B2 (en) 2017-07-31 2023-03-07 Medtronic, Inc. Therapeutic electrical stimulation therapy for patient gait freeze
CZ310035B6 (cs) * 2019-12-09 2024-05-29 Univerzita PalackĂ©ho v Olomouci N-(furan-2-ylmethyl)-7H-purin-6-amin pro modulaci cirkadiánních rytmů
US12453859B2 (en) 2021-02-24 2025-10-28 Medtronic, Inc. Posture state definition calibration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242941A (en) * 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
JP4228398B2 (ja) * 1997-04-23 2009-02-25 萬有製薬株式会社 神経ペプチドｙ受容体拮抗剤
AU8474298A (en) * 1997-07-31 1999-02-22 Bristol-Myers Squibb Company A method for modulation of circadian rhythmicity
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
EP1129089B1 (en) * 1998-11-10 2005-12-28 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
AU2935200A (en) * 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007145763A (ja) * 2005-11-28 2007-06-14 Tokyo Medical & Dental Univ 記憶障害抑制剤
KR101332243B1 (ko) * 2011-01-24 2013-11-25 애니젠 주식회사 생체리듬 조절용 조성물, 생체 리듬 장애 진단용 조성물 및 진단 키트

Also Published As

Publication number Publication date
AU2002351381A1 (en) 2003-06-30
CA2469790A1 (en) 2003-06-26
WO2003051356A1 (en) 2003-06-26
AU2002351381B2 (en) 2007-06-07
US20050107411A1 (en) 2005-05-19
EP1463499A1 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
US20050107411A1 (en) Method for treating circadian rhythm disruptions
JP2000514455A (ja) タキキニンアンタゴニストによるサーカディアンリズムの改変
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
Sack et al. Circadian rhythm sleep disorders: lessons from the blind
US20100249164A1 (en) Modulation of sleep with nr2b receptor antagonists
Mansouri et al. Effects of aging on 24-hour intraocular pressure measurements in sitting and supine body positions
WO2008157845A1 (en) Method of treating metabolic disorders and depression with dopamine receptor agonists
JP2020534270A (ja) １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
BR112019020798A2 (pt) métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
US20060003985A1 (en) Enhancement of sleep with t-type calcium channel antagonists
CA2957588C (en) Tasimelteon for treating smith-magenis syndrome
WO2021139874A1 (en) Cognitive disorder prevention and therapy
Breen et al. Sleep‐related motor and behavioral disorders: Recent advances and new entities
TWI759579B (zh) 睡眠障礙治療及預防
WO1998042331A1 (en) Mediation of circadian rhythms
Vela-Bueno et al. Melatonin, sleep, and sleep disorders
KR101589314B1 (ko) 수면 장애의 치료
R Jeffrey Goldsmith MD et al. The basics for psychiatrists: an overview of sleep, sleep disorders, and psychiatric medications' effects on sleep
US20190008188A1 (en) Antihistamines Combined with Dietary Supplements for Improved Health
Greydanus et al. Sleep disorders in adolescents
Aprison et al. A neurochemist's perspective on human depression and stress
Pandi-Perumal Sleep and Sleep Pharmacology
Vimmerová-Lattová Endocrine and Metabolic Aspects of Various Sleep Disorders
IL103411A (en) Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
Shah et al. Assessment and treatment of sleep disturbances in aged population

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090714